About CRA | Expertise | Consultants | Publications | News | Events | Offices | Careers                                                                         
Take a closer look. CRA provided accounting analysis and expert testimony in two cases
decided by the US Supreme Court regarding mutual fund fees, ultimately contributing
to our client’s successful defense.

Gregory K. Bell Publications

Pharma and biotech patent litigation
Gregory Bell

In the April–June 2014 edition of Corporate Disputes, Group Vice President and Global Practice Leader Dr. Gregory Bell and other industry experts discuss pharma and biotech patent litigation. To read ...Corporate Livewire Round Table: Biotech and Pharmaceutical
Gregory Bell

In Corporate Livewire's June 2013 Round Table "Biotech & Pharmaceutical," Dr. Gregory Bell and other leading experts discuss changes and analyze the effects they will have in the industry.To read ...Managing Dispute Resolution Strategy and Process
Gregory Bell

In the “Hot Topic” section in the July-September 2013 issue of Corporate Disputes, Dr. Gregory Bell and other industry experts discuss managing dispute resolution strategy and process.To read the article, click ...Arbitration in Toronto: An Economic Study
Gregory K. Bell, Andrew Tepperman

Consultants at Charles River Associates (CRA) studied the economic impact of arbitration activity in the City of Toronto and provided a forecast of the future economic significance for the city. ...TalkingPoint: Competitive Strategies In Life Sciences: Biobetters Versus Biosimilars

TalkingPoint: Competitive Strategies In Life Sciences: Biobetters Versus BiosimilarsGreg Bell, Practice Leader and Vice President, contributes to the November 2011 Financier Worldwide article titled Competitive Strategies In Life Sciences: Biobetters ...
CRA Insights: Life Sciences: February 2010
Gregory Bell, Rhett Johnson, Matthew Majewski, Peter Rankin, Tim Wilsdon

This is the first issue of our quarterly newsletter where CRA will analyze business trends in the marketplace and offer insights into subjects that affect the life sciences industry. Each ...Future Innovations and Structural Changes
Gregory K. Bell

Greg Bell answers the questions “What are some of the more significant structural changes that will shape our industry in the future?” and “Are pharmaceutical companies going to continue to ...Innovation in the Pharmaceutical Sector

The Enterprise DG of the European Commission commissioned Charles River Associates to undertake a study investigating whether there is a worldwide crisis in innovation in the pharmaceutical sector, the reasons ...Global Pricing Strategies for Pharmaceutical Product Launches
Peter Rankin, Gregory K. Bell, Tim Wilsdon

This article provides a brief strategic overview of the types of constraints that manufacturers must overcome in order to implement a successful global product launch and determine the optimum price. Click ...